PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B: A cross-sectional study of diagnostic accuracy.

Abstract Cell death markers, M65 and M30, have been suggested to be sensitive markers of liver inflammation and fibrosis in nonalcoholic fatty liver disease and chronic hepatitis C. Our aim was to investigate whether these markers were useful in diagnosing liver inflammation and fibrosis in chronic hepatitis B (CHB).We examined 186 patients with CHB; 18 sex- and age-matched healthy subjects were controls. The blood samples were collected from CHB patients within 1 week before or after liver biopsy. According to METAVIR score system, liver inflammation was graded from A0 to A3, and fibrosis from F0 to F4.Serum M65 and M30 levels were in parallel with the grades of liver inflammation. M65, not M30, increased significantly in patients with severe inflammation and normal alanine aminotransferase. M65 is one of the independent predictors of severe liver inflammation (≥A2). The levels of M65 and M30 levels significantly increased in parallel with the degree of inflammation in F1 patients, whereas they showed no statistical difference between different stages of fibrosis in A1 patients.Serum M65 is a useful indicator of liver inflammation in CHB patients. Serum M65, not M30, is valuable in the grading of liver fibrosis.
PMID
Related Publications

Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.

Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection.

Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis.

The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.

Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28514295
OWN - NLM
STAT- MEDLINE
DA  - 20170517
DCOM- 20170613
LR  - 20170613
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 20
DP  - 2017 May
TI  - Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis
      in chronic hepatitis B: A cross-sectional study of diagnostic accuracy.
PG  - e6807
LID - 10.1097/MD.0000000000006807 [doi]
AB  - Cell death markers, M65 and M30, have been suggested to be sensitive markers of
      liver inflammation and fibrosis in nonalcoholic fatty liver disease and chronic
      hepatitis C. Our aim was to investigate whether these markers were useful in
      diagnosing liver inflammation and fibrosis in chronic hepatitis B (CHB).We
      examined 186 patients with CHB; 18 sex- and age-matched healthy subjects were
      controls. The blood samples were collected from CHB patients within 1 week before
      or after liver biopsy. According to METAVIR score system, liver inflammation was 
      graded from A0 to A3, and fibrosis from F0 to F4.Serum M65 and M30 levels were in
      parallel with the grades of liver inflammation. M65, not M30, increased
      significantly in patients with severe inflammation and normal alanine
      aminotransferase. M65 is one of the independent predictors of severe liver
      inflammation (>/=A2). The levels of M65 and M30 levels significantly increased in
      parallel with the degree of inflammation in F1 patients, whereas they showed no
      statistical difference between different stages of fibrosis in A1 patients.Serum 
      M65 is a useful indicator of liver inflammation in CHB patients. Serum M65, not
      M30, is valuable in the grading of liver fibrosis.
FAU - Wei, Xinhuan
AU  - Wei X
AD  - aDepartment of Hepatitis C and Drug-induced Liver Injury, Beijing Youan Hospital 
      bDepartment of Gastroenterology, Beijing Ditan Hospital, Capital Medical
      University, Beijing, China.
FAU - Wei, Hongshan
AU  - Wei H
FAU - Lin, Wei
AU  - Lin W
FAU - Hu, Zhongjie
AU  - Hu Z
FAU - Zhang, Jing
AU  - Zhang J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0 (Keratin-18)
RN  - 0 (M65 antigen, human)
RN  - 0 (Peptide Fragments)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Biomarkers/blood
MH  - Biopsy, Needle
MH  - Cross-Sectional Studies
MH  - Female
MH  - Hepatitis B, Chronic/*blood/immunology/pathology
MH  - Humans
MH  - Keratin-18/*blood
MH  - Liver/*immunology/*pathology
MH  - Liver Cirrhosis/*blood/immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Peptide Fragments/*blood
MH  - Severity of Illness Index
MH  - Young Adult
PMC - PMC5440132
EDAT- 2017/05/18 06:00
MHDA- 2017/06/14 06:00
CRDT- 2017/05/18 06:00
AID - 10.1097/MD.0000000000006807 [doi]
AID - 00005792-201705190-00012 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 May;96(20):e6807. doi: 10.1097/MD.0000000000006807.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>